Management of Dual Antiplatelet Therapy in Post-Operative ACS Patients

Introduction to DAPT Management

The American College of Cardiology recommends initiating or resuming dual antiplatelet therapy as soon as hemostasis is secure in post-operative patients with acute coronary syndrome, as DAPT is a Class I recommendation for ACS regardless of bleeding risk 1, 2

For patients at high bleeding risk, including those with prolonged prothrombin time, the American Heart Association suggests that dual antiplatelet therapy should be modified but not eliminated, with a preference for clopidogrel over ticagrelor or prasugrel 1, 2, 3
The American College of Cardiology recommends that for ACS patients at high bleeding risk, a shortened DAPT duration of 6 months may be reasonable, rather than the standard 12-month duration, with a Class IIb, Level of Evidence C recommendation 5, 6

The American College of Cardiology recommends prescribing a proton pump inhibitor in combination with DAPT to reduce gastrointestinal bleeding risk, as a Class I recommendation 1, 2, 3, 4
The American Heart Association suggests using low-dose aspirin rather than higher doses when combined with a P2Y12 inhibitor 1, 3

The American College of Cardiology states that the thrombotic risk is highest in the first month after ACS, and DAPT interruption carries extreme risk of stent thrombosis and death 4
Elective surgery should be postponed if less than 1 month from ACS whenever possible, according to the American College of Cardiology 4

The American College of Cardiology recommends not completely withholding DAPT in post-operative ACS patients due to bleeding concerns, as the thrombotic risk typically outweighs bleeding risk, especially in the first 6 months 1, 2, 4
The American College of Cardiology advises against using prasugrel if the patient has prior stroke or TIA, as a Class III: Harm recommendation 5, 3